Enduring Material

The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study
View Activity Info
Enter Basic User Info
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

1800 Diagonal Road, Suite 360
Alexandria, VA 22314
General Information
Tuesday, December 5, 2023 - Thursday, December 5, 2024
60 minutes
National Psoriasis Foundation
Virtual Conference Room
Journal of Psoriasis and Psoriatic Arthritis
National Psoriasis Foundation
Objectives
  • To understand the impact psoriasis has on T2DM patients’ demographics, comorbidities, and health care outcomes.
  • Improved competence in recognizing T2D as a comorbidity of psoriasis and mitigating associated risk factors
Presentations and Speakers
The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study
  • Bruce Strober, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Psoriasis is believed to be a common comorbidity of type 2 diabetes mellitus (T2DM). Learn more about the impact psoriasis has on T2DM patients’ demographics, comorbidities, and health care outcomes.
Disclosure Statements
Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

Sam Koons, NPF Staff, has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
BMS - Consulting - Relationship Has Ended
Speakers:
Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
  • AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
  • CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
  • AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
  • Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended
Any financial relationship that was found to be relevant has been mitigated.

All relevant financial relationships have been mitigated.
This activity is supported by educational grants from Novartis.
Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
0 %
100 %
12/5/2023
Continue to Enduring Material